Results 221 to 230 of about 127,399 (321)

Prevalence and Factors Associated With Symptom Profiles of Disorders of Gut‐Brain Interaction in Obesity Before and After Treatment

Neurogastroenterology &Motility, EarlyView.
DGBI symptoms are common in obesity and have the potential to exacerbate negative health outcomes. In general, the prevalence of DGBI symptoms decreases after obesity treatment, but patients can also shift from one GI symptom profile to another. ABSTRACT Background & Aims Disorders of gut‐brain interaction (DGBI) in obesity could impair health outcomes.
Esther Colomier, Janita Halminen, Malin Björck, Gudrún Höskuldsdóttir, Karin Mossberg, My Engström, Björn Eliasson, Ville Wallenius, Lars Fändriks, Jan Tack, Hans Törnblom, Magnus Simrén   +11 more
wiley   +1 more source

Effects of meal regularity and snacking frequency on irritable bowel syndrome. [PDF]

Front Public Health
Ajabnoor SM.
europepmc   +1 more source

Is Acupuncture an Effective Treatment for Patients with Irritable Bowel Syndrome

, 2011
Amy L. Leber
openalex   +1 more source

Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner

, 2015
Chunqiu Chen, Meiling Lü, Qiuhui Pan, Jakub Fichna, Lijun Zheng, Kesheng Wang, Zhen Yu, Yongyu Li, Kun Li, Aihong Song, Zhongchen Liu, Zhenshun Song, Martin E. Kreis   +12 more
openalex   +2 more sources

A Review of the Mechanisms of Action of the Herbal Medicine, STW 5‐II, Underlying Its Efficacy in Disorders of Gut–Brain Interaction

Neurogastroenterology &Motility, EarlyView.
The pathophysiology of functional dyspepsia and irritable bowel syndrome includes altered motility, secretion, sensitivity to sensory signals, impaired epithelial barrier function, inflammation, and gut dysbiosis. The phytomedicine, STW 5‐II, represents a multi‐targeted approach, addressing these pathophysiologies.
Anita Annaházi, Rudolf Bauer, Thomas Efferth, Mohamed T. Khayyal, Michael Schemann, Gudrun Ulrich‐Merzenich, Christine Feinle‐Bisset   +6 more
wiley   +1 more source

Prediction of irritable bowel syndrome by integrating urine metabolites and gut microbiota. [PDF]

Sci Rep
Lee G, Lee MH, Park SE, Pak J, Bae S, Kwak S, Moon YH, Son HS.   +7 more
europepmc   +1 more source

Validation of the PROMIS Global Physical and Mental Health Scale for Gastrointestinal Disorders: A Large‐Scale Cross‐Sectional Survey

Neurogastroenterology &Motility, EarlyView.
The 4‐item revised version of the Hays model from the PROMIS Global Health Scale exhibits stronger psychometric properties than the original model. This ultra‐brief assessment tool is a reliable measure for evaluating quality of life in both gastrointestinal and non‐gastrointestinal cohorts.
Pragalathan Apputhurai, Olafur S. Palsson, Shrikant I. Bangdiwala, Ami D. Sperber, Antonina Mikocka‐Walus, Simon R. Knowles   +5 more
wiley   +1 more source

Remission of irritable bowel syndrome with lifestyle medicine. [PDF]

Pak J Med Sci
Shabbir P, Malik S, Naveed M, Anwar MF, Sheraz M, Waraich HZ.   +5 more
europepmc   +1 more source

Psychological and Clinical Factors Mediate Post‐COVID‐19 Irritable Bowel Syndrome

Neurogastroenterology &Motility, EarlyView.
ABSTRACT Background Exposure to COVID‐19 has been shown previously to be associated with a higher risk for irritable bowel syndrome (IBS). This study aimed to better explain this relationship using mediation analysis. Methods This post hoc analysis of a multicenter cohort study includes 623 patients with and without COVID‐19 infection. All participants
Keren Hod, Giovanni Marasco, Luigi Colecchia, Cesare Cremon, Maria Raffaella Barbaro, Giulia Cacciari, Francesca Falangone, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Egidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, M. Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz Akyol, Ferdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yağcı, Husnu Pullukcu, Berrin Yalınbas Kaya, Ali Tureyen, İbrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Calıskan, Goksel Bengi, Esra Ergun Alıs, Snezana Lukic, Meri Trajkovska, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjolund, Navkiran Tornkvist, Uday C. Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Piero Portincasa, Antonio Di Sabatino, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Daniele Salvi, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara, on behalf of GI‐COVID19 study group   +68 more
wiley   +1 more source

Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies. [PDF]

Front Immunol
Li X, Yuan Q, Huang H, Wang L.
europepmc   +1 more source